
|Articles|November 15, 2003
Allergan to buy Oculex for $230 million in cash
New York-Allergan Inc. will pay nearly $230 million in cash to acquire Oculex Pharmaceuticals Inc., a privately held company specializing in the development of treatments for sight-threatening diseases of the eye.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Improved grading scales for oncology drugs causing ocular adverse events
5













































.png)


